Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Repatha (evolocumab) injection gets FDA approval for high cholesterol

Repatha (evolocumab) injection gets FDA approval for high cholesterol

Invitae announces dramatic expansion of genetic testing menu

Invitae announces dramatic expansion of genetic testing menu

Using deep learning to analyze genetic mutations: an interview with Brendan Frey

Using deep learning to analyze genetic mutations: an interview with Brendan Frey

New NIH grants support research that combines DNA sequence information and electronic medical records

New NIH grants support research that combines DNA sequence information and electronic medical records

Familial hypercholesterolemia patients can benefit from alirocumab drug

Familial hypercholesterolemia patients can benefit from alirocumab drug

Young diabetic women have six-fold heart attack risk

Young diabetic women have six-fold heart attack risk

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Type 2 diabetes less common in patients with familial hypercholesterolemia

Type 2 diabetes less common in patients with familial hypercholesterolemia

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.